Antitumor and immunomodulation activities of polysaccharide from Phellinus baumii

International Journal of Biological Macromolecules

Volumn 91, Issue , 2016, Pages 1199-1205

  Liu, Ming Ming ^a   Zeng, Peng ^a   Li, Xiao Tong ^a   Shi, Lian Gen ^a  

^a ZHEJIANG UNIVERSITY   (China)

Author keywords

Antitumor; Immunomodulatory; Phellinus baumii; Polysaccharide

Indexed keywords

FLUOROURACIL; FUNGAL POLYSACCHARIDE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; IMMUNOLOGIC FACTOR; TUMOR NECROSIS FACTOR;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER ADJUVANT THERAPY; CELL CYCLE G0 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE REGULATION; CELL GROWTH; CELL PHAGOCYTOSIS; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG CYTOTOXICITY; DRUG PURIFICATION; EMBRYO; FEMALE; FLOW CYTOMETRY; FRUITING BODY; G1 PHASE CELL CYCLE CHECKPOINT; GASTRIC CANCER CELL LINE; HEK293 CELL LINE; HELA CELL LINE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOREGULATION; IN VITRO STUDY; MOUSE; NONHUMAN; PHELLINUS; PHELLINUS BAUMII; RAW 264.7 CELL LINE; S PHASE CELL CYCLE CHECKPOINT; SGC 7901 CELL LINE; ANIMAL; BASIDIOMYCETES; CELL CYCLE; CELL LINE; CHEMISTRY; DRUG EFFECTS; PHAGOCYTOSIS; SECRETION (PROCESS);

ANIMALS; ANTINEOPLASTIC AGENTS; BASIDIOMYCOTA; CELL CYCLE; CELL LINE; CELL PROLIFERATION; FUNGAL POLYSACCHARIDES; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-6; MICE; PHAGOCYTOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84978204217     PISSN: 01418130     EISSN: 18790003     Source Type: Journal    
DOI: 10.1016/j.ijbiomac.2016.06.086     Document Type: Article

References (32)

1. [1] World Health Organization, Cancer, Retrieved from http://www.who.int/mediacentre/factsheets/fs297/en/ (2011).
2. [2] Kim, H.M., Han, S.B., Oh, G.T., Kim, Y.H., Hong, D.H., Hong, N.D., Yoo, I.D., Int. J. Immunopharmacol. 18 (1996), 295–303.
3. [3] Cho, J.-H., Cho, S.-D., Hu, H., Kim, S.-H., Lee, S.K., Lee, Y.-S., Kang, K.-S., Carcinogenesis 23 (2002), 1163–1169.
4. [4] Ajith, T., Janardhanan, K., J. Ethnopharmacol. 84 (2003), 157–162.
5. [5] Han, S.B., Lee, C.W., Jeon, Y.J., Hong, N.D., Yoo, I.D., Yang, K.-H., Kim, H.M., Immunopharmacology 41 (1999), 157–164.
6. [6] Hannigan, G., Troussard, A.A., Dedhar, S., Nat. Rev. Cancer 5 (2005), 51–63.
7. [7] Borchers, A.T., Keen, C.L., Gershwin, M.E., Exp. Biol. Med. 229 (2004), 393–406.
8. [8] Yang, Q., Hu, X., Wan, Q., Wang, W., China J. Chin. Mater. Med. 31 (2006), 1713–1715.
9. [9] Hengartner, M.O., Nature 407 (2000), 770–776.
10. [10] Kim, G.-Y., Oh, Y.-H., Park, Y.-M., Biochem. Biophys. Res. Commun. 309 (2003), 399–407.
11. [11] Franz, G., Planta Med. 55 (1989), 493–497.
12. [12] Chihara, G., Preclinical evaluation of lentinan in animal models. Biological Response Modifiers in Human Oncology and Immunology, 2016, Springer, 1983, 189–197.
13. [13] Chihara, G., EOS J. Immunol. Immunopharmacol., 4, 1984.
14. [14] Matsuo, T., Arika, T., Mitani, M., Komatsu, N., Arzneimittelforschung, 32, 1982, 647.
15. [15] Zeng, P., Huang, S.-R., Liu, M.-M., Shi, L.-G., Sci. Seric. 41 (2015), 928–933.
16. [16] Dubois, M., Gilles, K.A., Hamilton, J.K., Rebers, P., Smith, F., Anal. Chem. 28 (1956), 350–356.
17. [17] Sliva, D., Harvey, K., Mason, R., Lloyd, F., English, D., Cancer Invest. 19 (2001), 783–790.
18. [18] Li, Y.-G., Ji, D.-F., Zhong, S., Liu, P.-G., Lv, Z.-Q., Zhu, J.-X., Chen, J.-E., Chen, H.-P., J. Ethnopharmacol. 150 (2013), 187–195.
19. [19] Duffield, J.S., Clin. Sci. 104 (2003), 27–38.
20. [20] Park, J.-S., Lee, E.-J., Lee, J.-C., Kim, W.-K., Kim, H.-S., Int. Immunopharmacol. 7 (2007), 70–77.
21. [21] Ge, Q., Zhang, A.-q., Sun, P.-l., Food Chem. 114 (2009), 391–395.
22. [22] Song, T.-Y., Lin, H.-C., Yang, N.-C., Hu, M.-L., J. Ethnopharmacol. 115 (2008), 50–56.
23. [23] Bae, J.S., Jang, K.H., Yim, H., Jin, H.K., Cancer Lett. 218 (2005), 43–52.
24. [24] Wang, C., Li, H.B., Li, S., Tian, L.L., Shang, D.J., Biochimie 94 (2012), 434–441.
25. [25] Lee, K.-H., J. Nat. Prod. 67 (2004), 273–283.
26. [26] Deshpande, S.S., Ingle, A.D., Maru, G., Cancer Lett. 118 (1997), 79–85.
27. [27] Li, G., Kim, D.H., Kim, T.D., Park, B.J., Park, H.D., Park, J.I., Na, M.K., Kim, H.C., Hong, N.D., Lim, K., Hwang, B.D., Yoon, W.H., Cancer Lett. 216 (2004), 175–181.
28. [28] Zhang, M., Chen, H., Huang, J., Li, Z., Zhu, C., Zhang, S., Life Sci. 76 (2005), 2115–2124.
29. [29] Zirk, N.M., Hashmi, S.F., Ziegler, H.K., Infect. Immun. 67 (1999), 319–326.
30. [30] Chang, Z.Q., Oh, B.C., Rhee, M.H., Kim, J.C., Lee, S.P., Park, S.C., World J. Microbiol. Biotechnol. 23 (2006), 723–727.
31. [31] Yoshikawa, R., Kusunoki, M., Yanagi, H., Noda, M., Furuyama, J.-i., Yamamura, T., Hashimoto-Tamaoki, T., Cancer Res. 61 (2001), 1029–1037.
32. [32] Suabjakyong, P., Nishimura, K., Toida, T., Van Griensven, L.J., Food Funct. 6 (2015), 2834–2844.